Over the past 12 months, 2 insiders at Aurinia Pharmaceuticals Inc. filed 15 open-market SEC Form 4 transactions on AUPH: 14 purchases worth $38.7M and 1 sale worth $210K. Insiders have been net buyers over this period. The most recent filing was on Jun 2, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 2, 26 | Kevin TangChief Executive Officer | BUY | 206.0K | $15.28 | $3.1M |
| Jun 1, 26 | Kevin TangChief Executive Officer | BUY | 343.5K | $15.34 | $5.2M |
| May 29, 26 | Kevin TangChief Executive Officer | BUY | 262.7K | $15.35 | $4.0M |
| Mar 3, 26 | Kevin TangDirector | BUY | 184.2K | $14.22 | $2.6M |
| Mar 2, 26 | Kevin TangDirector | BUY | 115.8K | $14.33 | $1.6M |
| Feb 27, 26 | Kevin TangDirector | BUY | 300.0K | $14.38 | $4.2M |
| Aug 5, 25 | Kevin TangDirector | BUY | 200.0K | $11.68 | $2.3M |
| Aug 4, 25 | Kevin TangDirector | BUY | 100.0K | $11.34 | $1.1M |
| Aug 1, 25 | Greg KeenanChief Medical Officer | SELL | 20.0K | $10.50 | $210K |
| Aug 1, 25 | Kevin TangDirector | BUY | 1.00M | $10.12 | $10.1M |
| Mar 7, 25 | Greg KeenanChief Medical Officer | SELL | 8.3K | $8.23 | $68K |
| Mar 4, 25 | Matthew Maxwell DonleyChief Operating Officer | SELL | 59.0K | $7.92 | $467K |
| Mar 4, 25 | Peter GreenleafChief Executive Officer | SELL | 164.9K | $7.92 | $1.3M |
| Mar 4, 25 | Joseph M MillerChief Financial Officer | SELL | 56.2K | $7.92 | $445K |
| Mar 4, 25 | Stephen P. RobertsonEVP, General Counsel | SELL | 57.6K | $7.92 | $456K |
| Mar 4, 25 | Kevin TangDirector | BUY | 500.0K | $8.09 | $4.0M |
| Mar 3, 25 | Matthew Maxwell DonleyChief Operating Officer | SELL | 65.9K | $8.00 | $527K |
| Mar 3, 25 | Peter GreenleafChief Executive Officer | SELL | 195.6K | $8.00 | $1.6M |
| Mar 3, 25 | Greg KeenanChief Medical Officer | SELL | 12.2K | $8.00 | $98K |
| Mar 3, 25 | Joseph M MillerChief Financial Officer | SELL | 61.9K | $8.00 | $495K |
| Mar 3, 25 | Stephen P. RobertsonEVP, General Counsel | SELL | 64.9K | $8.00 | $519K |
| Mar 3, 25 | Kevin TangDirector | BUY | 352.0K | $8.02 | $2.8M |
| Feb 28, 25 | Kevin TangDirector | BUY | 399.3K | $7.85 | $3.1M |
| Dec 9, 24 | Kevin TangDirector | BUY | 500.0K | $9.09 | $4.5M |
| Dec 6, 24 | Kevin TangDirector | BUY | 400.0K | $9.01 | $3.6M |
| Dec 5, 24 | Kevin TangDirector | BUY | 300.0K | $8.91 | $2.7M |
| Nov 11, 24 | Jeffrey Allen BaileyDirector | SELL | 4.6K | $8.43 | $38K |
| Nov 11, 24 | Karen L. SmithDirector | SELL | 5.2K | $8.43 | $44K |
| Aug 6, 24 | Scott Michael HabigChief Commercial Officer | SELL | 18.2K | $5.31 | $97K |
| May 21, 24 | Brinda BalakrishnanDirector | SELL | 520 | $5.74 | $3K |
| May 21, 24 | Daniel BillenDirector | SELL | 5.3K | $5.74 | $30K |
| May 21, 24 | David R.w. JayneDirector | SELL | 4.9K | $5.74 | $28K |
| May 21, 24 | Jill LeversageDirector | SELL | 5.6K | $5.74 | $32K |
| May 21, 24 | R. Hector Mackay-dunnDirector | SELL | 5.6K | $5.74 | $32K |
| Mar 6, 24 | Matthew Maxwell DonleyEVP, Ops & Strategy | SELL | 40.7K | $5.51 | $224K |
| Mar 6, 24 | Peter GreenleafChief Executive Officer | SELL | 127.0K | $5.60 | $711K |
| Mar 6, 24 | Scott Michael HabigChief Commercial Officer | SELL | 17.8K | $5.60 | $100K |
| Mar 6, 24 | Joseph M MillerChief Financial Officer | SELL | 34.8K | $5.60 | $195K |
| Mar 6, 24 | Stephen P. RobertsonEVP, General Counsel | SELL | 57.7K | $5.60 | $323K |
| Feb 27, 24 | Volker KnappertzEVP, Research and Development | SELL | 4.9K | $6.10 | $30K |
| Feb 20, 24 | Scott Michael HabigChief Commercial Officer | SELL | 15.9K | $5.48 | $87K |
| Feb 20, 24 | Volker KnappertzEVP, Research and Development | SELL | 25.1K | $5.48 | $138K |
| May 23, 23 | Daniel BillenDirector | SELL | 4.7K | $11.26 | $52K |
| May 23, 23 | David R.w. JayneDirector | SELL | 8.7K | $11.26 | $98K |
| May 23, 23 | Jill LeversageDirector | SELL | 4.8K | $11.26 | $54K |
| May 23, 23 | R. Hector Mackay-dunnDirector | SELL | 4.8K | $11.26 | $54K |
| May 19, 23 | Joseph P HaganDirector | SELL | 272 | $10.58 | $3K |
| Mar 2, 23 | Peter GreenleafChief Executive Officer | SELL | 33.0K | $8.94 | $293K |
| Mar 2, 23 | George M Milne JrDirector | BUY | 20.0K | $8.91 | $178K |
| Mar 2, 23 | Joseph M MillerChief Financial Officer | SELL | 11.4K | $8.94 | $101K |
Over the past 12 months, insiders at Aurinia Pharmaceuticals Inc. filed 14 open-market purchases worth $38.7M and 1 sale worth $210K on AUPH, which makes them net buyers over the period. The most recent Form 4 was filed on Jun 2, 26.
The largest recent open-market AUPH insider purchase in our data was $10.1M by Kevin Tang, Director, filed on Aug 1, 25.
2 different insiders at Aurinia Pharmaceuticals Inc. filed open-market SEC Form 4 transactions on AUPH over the last 12 months.
InsiderTape plots every AUPH insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Aurinia Pharmaceuticals Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →